MedTrace Logo

Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients

NCT05456243 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-10-14

No results posted yet for this study

Summary

This research study is being done to learn if an experimental treatment of infusing allogeneic adipose-derived mesenchymal stromal cells (allo-A-MSC ) directly into the renal artery is safe and can help reduce inflammation in the transplanted kidney and treat rejection.

Conditions

  • Kidney Transplant

Interventions

BIOLOGICAL

Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)

Single intra-arterial infusion of 1 x 10\^5 cells/kg

BIOLOGICAL

High dose adipose tissue derived mesenchymal stromal cells (A-MSC)

Single intra-arterial infusion of 5 x 10\^5 cells/kg infused over 5 minutes

Sponsors & Collaborators

Principal Investigators

  • Timucin Taner, MD, PhD · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-30
Primary Completion
2026-04-30
Completion
2026-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05456243 on ClinicalTrials.gov